Abstract. Melittin, a significant constituent of Apis mellifera (honeybee) venom, is a water-soluble toxic peptide that has traditionally been used as an antitumor agent. However, the underlying mechanisms by which it inhibits tumor cell growth and angiogenesis remain to be elucidated. In the present study, screening for increased cathepsin S (Cat S) expression levels was performed in MHCC97-H cells and various other hepatocellular carcinoma cell lines by reverse transcription-polymerase chain reaction and western blot analysis. A pcDNA3
Introduction
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors and the third leading cause of cancer-associated mortality globally (1, 2) . Despite significant improvements in surgical and drug treatments, the overall 5-year survival rate of HCC patients remains low (3) (4) (5) (6) (7) ; this is likely due to the high rate of recurrence and metastasis following curative resection and liver transplantation (8, 9) . It has been demonstrated that HCC metastasis is a multi-step process, involving invasion and degradation of extracellular matrix (ECM) proteins (10, 11) , translocation through the vasculature, subsequent migration to secondary sites and, finally, formation of metastatic nodules in future metastatic sites (12) . Angiogenesis is reported to be a significant factor in the proliferation and migration of HCC (13) . Although progress has been made in this field, more detailed research is required to investigate the mechanisms underlying HCC angiogenesis and metastasis.
Cathepsin S (Cat S), a member of the lysosomal cysteine cathepsin family, has been observed to play a significant role in cell proliferation, angiogenesis and metastasis (14) . As a cysteine protease, Cat S is primarily localized in lysosomes that are able to retain proteolytic activity at a neutral pH (15) . It has been demonstrated that Cat S is capable of being translocated from the lysosome to the cell surface and is ultimately released into the extracellular space (16, 17) . Furthermore, increased Cat S expression and activity has been associated with a number of malignancies, including HCC (18) , pancreatic (14) , breast (19) and prostate cancers (20) . Angiogenesis has been identified to be associated with the growth and metastasis of human tumors (21) . In addition, previous studies have indicated the significance of Cat S in tumor angiogenesis (17) . Therefore, Cat S has become a compound of interest (18, 22) and has been suggested as a potential therapeutic target for the suppression of tumor angiogenesis (18) .
A previous study reported that vascular endothelial growth factor (VEGF) is essential for endothelial cells and plays a significant role in angiogenesis, tumor progression and vascular permeability (23) . VEGF receptor 2 (VEGFR-2) is regarded as the most biologically important receptor for VEGF (24) . VEGF has been observed to be frequently expressed in HCC (25) , and is important in HCC proliferation and migration (26) . Additional evidence has revealed that the VEGF-A/VEGFR-2/mitogen-activated protein kinase 1 (MEK1)/extracellular signal-regulated kinase (ERK)1/2 signaling pathway plays a central role in human cancer (27) . However, the role of the VEGF-A/VEGFR-2/MEK1/ERK1/2 signaling pathway in HCC proliferation, invasion and angiogenesis is complex and remains to be elucidated.
Melittin is a water-soluble toxic peptide, produced by the honeybee, Apis mellifera. It is a small amphipathic peptide composed of 26 amino acids, with antitumor and antibacterial characteristics (28) (29) (30) (31) (32) (33) . Evidence has accumulated indicating that melittin is capable of causing growth arrest and exerting cytotoxic effects in HCC (34) (35) (36) . It has been demonstrated that melittin is a significant factor in VEGF-A-induced angiogenesis via blocking of VEGFR-2 and the cyclooxygenase-2-mediated mitogen-activated protein kinase signaling pathway in endothelial cells (36) . Melittin is thus considered to be an attractive anticancer therapeutic candidate (37) . However, it is unclear at present whether melittin is able to regulate proliferation, invasion and angiogenesis via blocking of the VEGF-A/VEGFR-2/MEK1/ERK1/2 signaling pathway in MHCC97-H cells.
In the present study, interactions between melittin and Cat S-induced proliferation, invasion and angiogenesis in HCC, and the influence on the VEGF-A/VEGFR-2/MEK1/ERK1/2 signaling pathway were investigated. Initially, various hepatic cancer cell lines were screened for increased levels of Cat S expression. As MHCC97-H cells were identified to exhibit the highest expression levels of Cat S, the role of melittin and its effects on Cat S and the VEGF-A/VEGFR-2/MEK1/ERK1/2 signaling pathway were investigated in vitro in these cells.
Materials and methods
Cell lines, cell culture and reagents. Melittin (>90% pure) was obtained from Sigma-Aldrich (#M4171, St. Louis, MO, USA). A 5 µg/ml solution of melittin was prepared in sterile water, stored at -20˚C and diluted to the required concentrations for the experiments performed. MHCC97-H, Bel-7402, LO2, HepG2, SMMC7721, Hep3B, HepG2, Huh7 cells and HUVECs were purchased from the Shanghai Institutes of Biological Sciences, Chinese Academy of Sciences (Shanghai, China). Mouse anti-human antibodies against: Cat S (#sc-271619), anti-VEGF-A (#sc-53463) and anti-β-actin (#47778), were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Rabbit anti-human antibodies against: Phospho-VEGF receptor 2 (Tyr1175; #2478S), phospho-ERK1/2 (Thr202/Tyr204; #4370), ERK1/2 (#9194), phospho-MEK1 (Thr286; #9127S), MEK1(#12671), phospho-c-Raf (Ser259; # 9421S) and Raf (#9422S) were sourced from Cell Signaling Technology (Danvers, MA, USA).
Rabbit anti-Ras was purchased from Epitomics (#1819-1; Burlingame, CA, USA). Matrigel (#356234) was obtained from BD Biosciences (San Jose, CA, USA). XTT stock solution (#M2128-1G) and Lipofectamine 2000 (#11668-027) was purchased from ThermoFisher Scientific, Inc. Hematoxylin solution (#KGA223) was purchased from Nanjing Sai hong rui Biological Technology Co., Ltd. (Nanjing, China). 24-well Transwell (#FK-cn018), BCA Protein Assay Kit (#23225) and chemiluminescence detection reagents (#32209) were purchased from ThermoFisher Scientific, Inc. Mitomycin C was purchased from Sigma-Aldrich. Highly specific quantitative sandwich ELISA kit for human VEGF was obtained from RayBiotech (#MAB293, Norcross, GA, USA). Endothelial cell medium and fetal bovine serum (FBS) were purchased from ScienCell (Carlsbad, CA, USA). All cells were grown at 37˚C in a humidified atmosphere containing 5% CO 2 .
RNA extraction and reverse transcription-polymerase chain reaction (RT-PCR).
Total RNA was isolated using TRIzol ® reagent (#15596-026; Invitrogen; Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's protocols. Total RNA concentration and purity were determined by absorbance at 260 and 280 nm using a NanoVue Plus (#ND200: Gene Company Ltd.). Total RNA was reverse transcribed to complementary DNA (cDNA) using Superscript Reverse Transcriptase (Gibco; Thermo Fisher Scientific). cDNA was stored at -20˚C until use. The following primers were used in the experiments: Cat S forward, 5'-ACG GCT TTC CAG TAC ATC ATT GAT-3', and reverse, 5'-CTT TGT AGG GAT AGG AAG CGT CTG-3'; actin forward, 5'-CAC CCA GCA CAA TGA AGA TCA AGA T-3', and reverse, 5'-CCA GTT TTT AAA TCC TGA GTC AAG C-3'. RT-PCR was performed using the FastStart Universal SYBR ® Green Master (#04913914001; Roche Ltd.). PCR experiments were performed in triplicate.
Cell transfection. In order to establish small hairpin RNA (shRNA)-Cat S-stably transfected cell lines, MHCC97-H cells at 70-80% confluence were transfected with 1 µg pcDNA3.1-shRNA-Cat S (shRNA/MHCC97-H) or pcDNA3.1 empty vectors (Mock/MHCC97-H: F 5'-UUC UCC GAA CGU GUC ACGU-3' and R 5'-ACG UGA CAC GUU CGG AGAA-3') utilizing Lipofectamine ® 2000 (Invitrogen; Thermo Fisher Scientific). The plasmid (pcDNA3.1-shRNA-Cat S) containing shRNA-Cat S Gene Operon was purchased from Caliper Life Sciences (PerkinElmer, Inc. Waltham, MA, USA). In order to obtain stable transformants, cells were selected with Geneticin (G418; 500 µg/ml; #108321; MP Biomedicals Ltd, Shanghai, China) following 24 h transfection. After a total of 3 weeks growth, the remainder of cells were plated with fresh Dulbecco's modified Eagle's medium (DMEM)/G418 (500 µg/ml) and 10% FBS in 96-well plates, until a single colony was formed. Subsequently, individual colonies were isolated from these cultures and expanded for in vitro study.
The pairs of Cat S RNA oligonucleotide sequences and the pair of control RNA oligonucleotide sequences were designed and synthesized by Shanghai GenePharma Co., Ltd (Shanghai, China). The primer sequences of Cat S utilized were as follows: Forward 5'-CGC AAA TGG GCG GTA GGC GTG-3' , and reverse 5'-CAG CGG GGC TGC TAA AGC GCA TGC-3'. HUVEC cells were transfected with the Cat S (Cat S-HUVECs) or with the vector alone (Mock-HUVECs). Cell lines were incubated in an atmosphere of 5% CO 2 in air, at 37˚C with DMEM containing 10% FBS. HUVEC cells were seeded into 6-well plates and grown to 50-60% confluence for 20-24 h prior to transfection. For transfection, Lipofectamine 2000 was mixed with 20 nM RNAs according to the manufacturer's protocols.
Cell proliferation assay. The quantity of viable cells in culture was determined by employing a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cells (1x10 3 ) were seeded into a 96-well flat-bottomed titer plate and incubated for 24 h at 37˚C in a humidified atmosphere containing 5% CO 2 . Subsequently, 10 µl MTT stock solution (5 mg/ml; Sigma-Aldrich) was added to each well, and additional incubation was performed for 4 h at 37˚C. Adding 150 µl dimethyl sulfoxide (DMSO) to each well halted the reaction, and spectrophotometric absorbance was subsequently measured using a microplate reader (Model 3550; Bio-Rad Laboratories, Inc., Hercules, CA, USA) at 490 nm. The inhibition rate (%) was calculated as follows: (OD control group -OD experiment group)/(OD control group -OD blank group). Flat plate colony formation assay. MHCC97-H cells were collected and plated in 6 cm² culture plates (1x10 3 cells/well) for colony formation. Cells were incubated at 37˚C in a 5% CO 2 atmosphere and treated with various concentrations of melittin (4 or 8 µg/ml) for 24 h. At the conclusion of treatment, cells were washed twice with phosphate-buffered saline (PBS) and subsequently incubated in 9 ml drug-free medium for 14 days, to allow colony formation of surviving cells. Following 14 days of incubation, colonies were washed with chilled PBS and fixed using 4% neutral-buffered formalin for 10 min, followed by staining with hematoxylin solution and counting of colony numbers (>50 cells was defined as a colony). The results are representative of three independent experiments.
Wound healing migration assay. MHCC97-H cells (8x10 5 ) were grown to 100% confluence in 6-well plates and subsequently incubated with 8 µg/ml Mitomycin C for 3 h, in order to inactivate cell proliferation. Confluent cells were subsequently scratched using a pipette with a 200-µl tip and incubated for 24 h in a CO 2 incubator with a humidified atmosphere. Wounded cells were supplemented with a cell medium of 0.5% FBS and exposed to various concentrations (0, 4 or 8 µg/ml) of melittin. Images of MHCC97-H cells were captured following 24 h of incubation. The number of migrated cells in 6-8 randomly chosen fields for each well were counted under inverted microscope. Three independent experiments were performed.
Transwell migration assay. Each well of the pre-chilled, 24-well Transwell (Corning Inc., Corning, NY, USA) plates was coated with 60 µl 1:8 diluted Matrigel (growth factor reduced) and incubated for 5 h. Cells (1x10 5 /well) were seeded into the inner compartment of the invasion chamber with 200 µl 0.2% FBS/DMEM and various concentrations (4 or 8 µg/ml) of melittin. The inner chamber was placed into the outer chamber of the Transwell, which contained 500 µl 1% FBS/DMEM. Following incubation overnight, membranes were washed, and migrated cells were fixed using 4% paraformaldehyde with 0.5% crystal violet. Images were captured using an IX70 inverted microscope (Olympus Corporation, Tokyo, Japan) and the number of migrated cells was counted in 6-8 randomly selected fields. The number of invaded cells was quantified by manual counting relative to that of untreated controls.
ELISA assays for secretion of VEGF. MHCC97-H cells (5x10 5 ) were seeded into 6-well plates, incubated at 37˚C in 5% CO 2 atmosphere and treated with various concentrations of melittin. Cells were removed following 24 h of incubation, and culture medium was collected and used in order to determine the secretion of VEGF, using the VEGF ELISA kit in accordance with the manufacturer's protocol.
Tube formation assay. Pre-chilled 24-well plates were coated with 50 µl Matrigel (growth factor reduced) and incubated for 1 h at 37˚C. The cells (1x10 5 ) were placed in 200 µl DMEM (supplemented with 0.1% FBS) with various concentrations of melittin (4 or 8 µg/ml). Following 8 h incubation, the endothelial cell tubular structure had formed. The tube area from 5 random fields per well were photographed using a high power Axiovert S100 light microscope (Carl Zeiss AG, Jena, Germany) at x100 magnification. The lengths of tubes were measured using Image-Pro Plus software 4.5 (Media CyberMetics, Inc, Rockville, MD, USA). This experiment was repeated three times in triplicate. Data are expressed as the mean ± standard deviation.
Western blot analysis. Cells were harvested and washed twice with cold PBS and lysed in buffer (Beyotime Institute of Biotechnology, Shanghai, China). Samples were subsequently centrifuged for 30 min at 2,250 x g at 4˚C, and supernatant was collected as total cell lysate. Protein concentration was measured using a bicinchoninic acid kit (Thermo Fisher Scientific). Approximately 40 µg cellular proteins were separated using 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. Following blocking with 5% fat-free dry milk in 125 mM sodium chloride, 0.05% Tween-20 and 25 mM Tris base (1X TBS-T) for 1 h, cells were exposed overnight to primary antibodies (dilution, 1:1,000) against Cat S, phospho-VEGFR-2, VEGF-A, Ras, phospho-Raf, Raf, phospho-MEK1/2, MEK1/2, phospho-ERK1/2, ERK1/2 and β-actin. Following washing 3 times with 1X TBS-T for 10 min, the samples were incubated with secondary antibodies (dilution, 1:2,000) for 1 h. Membranes were subsequently incubated with enhanced chemiluminescence detection reagents (Thermo Fisher Scientific) according to the manufacturer's protocols. The antibody-specific proteins were visualized using an image analyzer (LAS-3000; Fujifilm, Tokyo, Japan) according to the manufacturer's protocol.
Statistical analysis. Data were expressed as the mean ± standard deviation. Statistical analysis was performed using SPSS software, version 16.0 (SPSS, Inc., Chicago, IL, USA). The significance of the difference between the experimental group and the control group was analyzed using a Student's t-test. P<0.05 was considered to indicate a statistically significant difference.
Results

Cat S is overexpressed in MHCC97-H cell lines.
In order to elucidate the role of Cat S in HCC invasion and angiogenesis, Cat S messenger RNA (mRNA) and protein expression levels were measured in 7 HCC cell lines using RT-PCR and western blotting. It was revealed that Cat S mRNA and protein expression were highest in the MHCC97-H cell line, compared with the L02 normal liver cell line and other HCC cell lines (Bel-7402, HepG2, MHCC97-L, Hep3B, Huh7, and SMMC7721) investigated (Fig. 1A and B) .
Although Cat S is considered to have a significant role in angiogenesis, invasion and metastasis in a number of tumor cell lines (38) , it remains to be determined whether it exerts any effects in HCC cell lines. Therefore, the MHCC97-H cell line was chosen as a model cell for the present study.
Melittin prevents MHCC97-H cell invasion, metastasis and angiogenesis.
It has previously been demonstrated qualitatively that Cat S was aberrantly overexpressed in human tumor tissues of HCC patients (25) . It is plausible that the activity of Cat S contributes to the invasion and metastasis of HCC cells. In order to investigate this hypothesis, the association between cell motility and Cat S expression was investigated in MHCC97-H cells, which were stably transfected with pcDNA3.1-shRNA-Cat S (shRNA-Cat S/MHCC97-H) or pcDNA3.1 empty vectors (Mock/MHCC97-H). Downregulation of Cat S in MHCC97-H cells was confirmed using western blotting. As shown in Fig. 2A , the levels of Cat S expression were significantly inhibited following transfection with pcDNA3.1-shRNA-Cat S, compared with MHCC97-H cells transfected with empty vectors.
Cat S has been demonstrated to be a significant factor in the degradation of ECM elements, and is closely associated with regulation of tumor cell invasion and metastasis (35) . It is possible that Cat S additionally regulates the metastasis of HCC cells (39) . Therefore, in the present study, an MTT cell assay was performed to determine whether shRNA-Cat S affects the proliferation of MHCC97-H cells. As shown in (Fig. 2B) , shRNA-Cat S significantly reduced the growth of shRNA-Cat S/MHCC97-H cells, compared with that of Mock/MHCC97-H cells.
A previous study demonstrated that melittin was able to significantly inhibit the growth of the SMMC-7721 HCC cells (40) . It is possible that melittin affects MHCC97-H cell invasion and angiogenesis via inhibition of Cat S activity (22, 35) . In order to test this hypothesis, the effects of melittin treatment on the viability of MHCC97-H cells were investigated in the present study using a XTT assay. As demonstrated in Fig. 2C , the present study determined the IC 50 of melittin in shRNA-Cat S/MHCC97-H cells to be 9.94 µg/ml; in Mock/MHCC97-H cells, the IC 50 was 4.03 µg/ml. The results indicated that the viability of melittin-treated Mock/MHCC97-H cells was significantly reduced compared with that of melittin-treated shRNA-Cat S/MHCC97-H cells. These results support the hypothesis that melittin is capable of inhibiting MHCC97-H cell viability, and that this is correlated with increased expression levels of the Cat S oncogene.
The present study subsequently investigated whether melittin was able to inhibit long-term clonogenic survival of MHCC97-H cells, using a colony formation assay. As demonstrated in Fig. 2D and E, in the control (0.1% DMSO treatment) group, shRNA-Cat S/MHCC97-H cells (45.5±1.7%) exhibited significantly reduced colony formation compared with Mock/MHCC97-H cells (82.1±9.3%). Notably, treatment with melittin was able to markedly reduce the number of colonies formed in Mock/MHCC97-H cells relative to the control treatment group (4 µg/ml and 8 µg/ml of melittin treated Mock/MHCC97-H cells was 36.1±8.7% and 6.5±8.9%, respectively P<0.05), however, it did not markedly reduce the colony growth rates in shRNA-Cat S/MHCC97-H cells (4 µg/ml and 8 µg/ml of melittin treated shRNA-Cat S/MHCC97-H cell was 40.7±1.2% and 26.4±1.6%, respectively), indicating that melittin specifically inhibits Cat S-induced colony formation.
Subsequently, the present study investigated the effects of melittin on MHCC97-H cell migration using Transwell chamber and wound-healing assays. In the wound healing assay (Fig. 2F and G significantly reduced compared with that of shRNA-Cat S/MHCC97-H cells (4 µg/ml and 8 µg/ml of melittin treated shRNA-Cat S/MHCC97-H cell was 31.7±2.1% and 25.8±3.5 %respectively; Fig. 2H and I ). These results suggest that melittin was able to effectively suppress Cat S-induced migration and invasion. ELISA was used to detect and quantify VEGF in the melittin-treated cell culture supernatant. It was revealed that treatment with melittin markedly suppressed secretion of VEGF from Mock/MHCC97-H cells into the cell culture supernatant: The VEGF level for DMSO treated cells, 4 µg/ml and 8 µg/ml of melittin treated Mock/MHCC97-H cells was 265.5±8.1, 140.9±9.4 and 91.7±7.9, respectively P<0.05; compared with shRNA-Cat S/MHCC97-H cells. The VEGF level for DMSO, 4 µg/ml and 8 µg/ml of melittin treated shRNA-Cat S/MHCC97-H cells was 198.2±14.5, 170.1±11.8 and 157.5±12.1, respectively (Fig. 2J) . The results indicate that Cat S may play a significant role as a target for angiogenesis inhibition by melittin.
Melittin inhibits Cat S-induced invasion and angiogenesis
of HUVECs. Considering that melittin treatment was able to significantly inhibit Mock/MHCC97-H cell migration, invasion and angiogenesis, the present study additionally investigated the effects of melittin inhibition on Cat S-induced angiogenesis in HUVECs.
In order to confirm the inhibitory effects of melittin on Cat S-induced invasion and angiogenesis in HUVECs, HUVECs were transfected with Cat S RNA (Cat S-HUVECs) to induce overexpression of Cat S, or with the empty vector (Mock-HUVECs). As demonstrated in Fig. 3A, an increase in the level of Cat S protein was observed in Cat S-HUVECs, whilst no such increase was observed in Mock-HUVECs.
Subsequently, the effects of melittin on HUVEC motility were investigated by Transwell assay. As shown in Fig. 3B and C, Cat S-HUVECs in the control group (76.4±4.1%) demonstrated an increase in the percentage of invading cells compared with Mock-HUVECs (35.2±3.5%). In the melittin-treated groups, the percentage of invading Cat S-HUVECs (4 µg/ml and 8 µg/ml of melittin treated Cat S-HUVECs was 25.6±4.5 and 4.6±2.4%, respectively, P<0.05) was significantly reduced relative to the control group (76.4±4.1%), whilst the migration of Mock-HUVECs was not: The migration rate for DMSO, 4 µg/ml and 8 µg/ml of melittin treated Mock-HUVECs was 35.2±3.5, 31.2±3.8 and 24.1±3.6%, respectively.
In order to determine whether melittin was capable of direct anti-angiogenic effects in Cat S-HUVECs, an endothelial cell tube formation assay was performed. In the control group (0.1% DMSO), Cat S-HUVECs formed a robust and more complete tube-like network (94.3±2.1 branch points) compared with Mock-HUVECs (67.3±2.1 branch points; Fig. 3D and E). As predicted, there was a significantly reduced number and length of tube structures in Cat S-HUVECs with increased concentrations of melittin (4 µg/ml and 8 µg/ml of melittin treated Cat S-HUVECs was 37.1±1.4 and 1.82±1.2 branch points, respectively; P<0.05). However, no such reduction was observed in Mock-HUVECs (4 µg/ml and 8 µg/ml of melittin treated Mock-HUVECs was 45.5±1.7 and 39.1±2.5 branch points, respectively).
Melittin inhibits Cat S expression in HCC cell lines.
In order to understand the effects of melittin on Cat S activity and expression, additional HCC cell lines with relatively high levels of Cat S expression were selected ( Fig. 1A and B) , including MHCC97-H, MHCC97-L and Bel-7402 cells, for additional measurements. Cells were treated with 0.1% DMSO (control) or melittin (4 or 8 µg/ml), for 24 h. Following incubation, total cell lysates were prepared and the level of Cat S proteins was determined using western blot analysis. The results revealed that melittin inhibited Cat S expression in MHCC97-H cells more markedly than in MHCC97-L and Bel-7402 cells (Fig. 4) , thereby further supporting the hypothesis that melittin is a Cat S inhibitor.
Melittin inhibits the activation of Cat S-mediated signaling pathways in stably transfected MHCC97-H cells.
In order to clarify whether melittin was capable of inhibiting Cat S-induced migration, invasion and angiogenesis via blocking of the VEGF-A/VEGFR-2/MEK1/ERK1/2 signaling pathway in MHCC97-H cells, Cat S gene expression was silenced in MHCC97-H cells and the cells were treated with various concentrations of melittin. Protein levels from cells exposed to various concentrations of melittin treatment were measured using western blotting, and probed with specific 
Discussion
Previous studies have implicated Cat S in the processes of invasion and metastasis in several types of malignancy (14, 41) . In addition, the overexpression and secretion of Cat S by tumor cells has been observed to positively increase tumor invasiveness (42, 43) . Therefore, inhibition of Cat S-induced invasion and angiogenesis may be a potential therapeutic strategy for the treatment of cancer (38) . Although progress has been made in this field, the function of Cat S in HCC progression and metastasis has not been fully elucidated. In the present study, it was identified that Cat S protein and mRNA were expressed at increased levels in MHCC97-H cells, which demonstrate high metastatic potential. In order to confirm the effects of Cat S on the invasion and angiogenesis of HCC cells, the present study utilized shRNA knockdown and overexpression of Cat S; this demonstrated that Cat S was able to promote MHCC97-H cell and HUVEC migration and angiogenesis, respectively.
A number of studies have reported that certain natural products may possess significant potential as anti-angiogenic agents for the control of cancer development and metastasis (44) . It was proposed by Gajski et al (37) that melittin may be a potential candidate for a cancer treatment strategy utilizing natural products. However, the mechanisms underlying the inhibitory action of melittin on Cat S-induced invasion and angiogenesis in MHCC97-H cells remain to be elucidated.
In the present study, the effects of melittin on Cat S-induced invasion and angiogenesis in stably transfected MHCC97-H cells were investigated using cell proliferation, cell viability, flat plate colony formation, wound healing, migration, Transwell migration and ELISA assays. It was revealed that melittin was able to significantly inhibit Mock/MHCC97-H cell invasion, migration and angiogenesis in a dose-dependent manner; however, it did not affect shRNA-Cat S/MHCC97-H cells. Similarly, melittin treatment was able to significantly inhibit invasion and tube formation of Cat S-HUVECs in a concentration-dependent manner. It thus appears that melittin exerted a direct inhibitory effect on Cat S-induced invasion and angiogenesis in vitro.
Angiogenesis is considered to be crucial in the growth, invasion and metastatic spreading of cancer (45) , and inhibition of angiogenesis provides a potential strategy for the modulation of cellular growth and prevention of malignancies (46) . The VEGF-A/VEGFR-2/Ras/Raf/MEK1/ERK1/2 signaling pathway has been identified as a potentially significant target for anti-angiogenic tumor therapy (47, 48) . It is well known that the biological functions of VEGF in angiogenesis, including microvascular permeability, invasion, migration and survival, are primarily mediated through VEGFR-2 (49) . Melittin has been demonstrated to play an important role in the inhibition of angiogenesis and metastasis, through decreasing VEGF and VEGFR-2, and blocking the VEGFR-2/Ras/Raf signaling pathway via interfering with the activation of MEK1/ERK1/2 (50) . In the present study, it was identified that melittin specifically abrogated phosphorylation/activation of Cat S, VEGF-A, p-VEGFR-2, Ras, p-Raf, p-MEK1 and p-ERK 1/2 in Mock/MHCC97-H cells; however, it exerted little effect on the shRNA-Cat S/MHCC97-H cells. This finding demonstrated that melittin was able to significantly inhibit the activation of VEGF-A/VEGFR-2/MEK1/ERK1/2 protein kinases in a concentration-dependent manner, in Mock/MHCC97-H cells in vitro, suggesting that modulation of Cat S expression may underlie the anticancer effects of melittin.
In conclusion, the present study demonstrated that Cat S may be a significant regulator of growth and angiogenesis in MHCC97-H cells, and that melittin is capable of inhibiting Cat S-induced invasion and angiogenesis via blocking of the VEGF-A/VEGFR-2/MEK1/ERK1/2 signaling pathway, in a dose-dependent manner. Furthermore, the present study provides additional evidence for the anti-angiogenic role of melittin. Melittin may be considered as a selective Cat S inhibitor, which possesses potential therapeutic value for the treatment of HCC cases exhibiting increased levels of Cat S expression.
